Would you like to receive important updates about Vertex Pharmaceuticals Inc like earnings dates and more?
The Year To Date (YTD) return is +3.31%.
The 52 Week Low stock price is 74.55 set on Tue, Jan 24, 2017 which is 361 days ago.
The current price per share is 111.90% above the 52 week low.
The 52 Week High stock price is $167.85 set on Tue, Jul 25, 2017 which is 179 days ago.
The current price per share is -5.89% below the 52 week high.
The All Time High stock price is $167.85 set on Tue, Jul 25, 2017 which is 179 days ago.
The current price per share is -5.89% below the all time high.
The Vertex 5 year stock chart shows the historical prices over the previous 60 months.
The Vertex 1 year stock chart shows the historical prices over the previous 12 months.
The 50 Day Moving Average is at $146.31 which is 7.97% below the stock price of $157.97.
The 200 Day Moving Average is at 109.99 which is 43.62% below the stock price of $157.97.
Because both the 50 DMA and 200 DMA are below the current stock price, this can be considered a bullish technical indicator.
Vertex Pharmaceuticals Inc is a Health Care stock that trades on the NASDAQ and has a market capitalization of $40.15 Billion.
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are ORKAMBI and KALYDECO. ORKAMBI (lumacaftor in combination with ivacaftor) is approved as a treatment for patients having two copies (homozygous) of the Delta-F508 (F508del) mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO (ivacaftor) is approved for the treatment of CF patients having the G551D mutation or other specified mutations in their CFTR gene. The Company's development programs in the field of CF include Tezacaftor (VX-661), VX-152, VX-440, VX-659, VX-445 and VX-371. VX-152, VX-440, VX-659 and VX-445 are CFTR corrector compounds.
For more information and analysis about Vertex Pharmaceuticals Inc, visit their web site at http://www.vpharm.com. For a real time price lookup on this ticker, VRTX, visit Google Finance and Bloomberg.
Below are several other Biotech & Pharma stocks include AbbVie Inc (ABBV), Allergan PLC (AGN), Alexion Pharmaceuticals Inc (ALXN), Amgen Inc (AMGN), Biogen Inc (BIIB), BioMarin Pharmaceutical Inc (BMRN), Bristol-Myers Squibb Co (BMY), Celgene Corp (CELG), Endo International PLC (ENDP), Gilead Sciences Inc (GILD), .
The EPS is $0.78.
The P/E Ratio is 202.47%.
Vertex has a relatively high price to earnings ratio compared to the overal S&P 500 average, which is about 25%.
Some investors look for very low p/e stocks with the hopes of investing in an undervalued stock. Of course, this is just one factor to consider.
The Earnings Release Date was Wed, Oct 25, 2017.
Since this earnings release 87 days ago, the stock price is up by +4.54%.2018-01-31 06:00:002018-01-31 13:00:00America/New_York0VRTX) Earnings , after the market close,Visit http://www.symbolsurfing.com/VRTX for more information.United StatesSymbol Surfing[email protected]
The next Earnings Release Date is, after the market close, on Wed, Jan 31, 2018, which is in 11 days.
VRTX currently does not pay a dividend.
Investors should understand the dividend history of a company. Dividend history will show the dividend payments disbursed to investors over the years.